Search

Your search keyword '"Scoazec, Jean Yves"' showing total 2,142 results

Search Constraints

Start Over You searched for: Author "Scoazec, Jean Yves" Remove constraint Author: "Scoazec, Jean Yves"
2,142 results on '"Scoazec, Jean Yves"'

Search Results

202. Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma

205. Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma.

209. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies

210. Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival

211. Sympathetic axonal sprouting induces changes in macrophage populations and protects against pancreatic cancer

213. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

215. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells

216. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy

225. Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma.

226. A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma

227. TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth

228. Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancers

230. Cancer Induces a Stress Ileopathy Depending on β-Adrenergic Receptors and Promoting Dysbiosis that Contributes to Carcinogenesis

244. Case Report: Response to Immunotherapy, Can Radiotherapy Be a Troublemaker?

245. 277 Safety and efficacy of intratumoral ipilimumab with IV nivolumab in metastatic melanoma. The NIVIPIT trial

246. 284 Integrated molecular characterization of primary resistance mechanisms to immune checkpoint blockade in advanced non-small cell lung carcinoma (a-NSCLC)

247. Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience

248. Mutational signatures in esophageal squamous cell carcinoma from eight countries with varying incidence

Catalog

Books, media, physical & digital resources